<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, March 6, 2018 (HealthDay News) — A single prostate-specific antigen (PSA) screening is not associated with a significant difference in prostate cancer mortality after follow-up of 10 years, but is associated with increased detection of low-risk prostate cancer, according to a study published in the March 6 issue of the Journal of the American Medical Association<\/i>.<\/p>\n
Richard M. Martin, Ph.D., from the University of Bristol in the United Kingdom, and colleagues invited 419,582 men aged 50 to 69 years at 573 primary care practices to attend a PSA testing clinic and receive a single PSA test versus standard practice (unscreened).<\/p>\n
The analysis included 189,386 men in the intervention group and 219,439 in the control group. The researchers found that after a median follow-up of 10 years, the rate of death from prostate cancer was 0.30 and 0.31 per 1,000 person-years in the intervention and control groups, respectively (rate ratio, 0.96; 95 percent confidence interval, 0.85 to 1.08; P = 0.50). A higher number was diagnosed with prostate cancer in the intervention versus the control group (4.3 versus 3.6 percent; rate ratio, 1.19; 95 percent confidence interval, 1.14 to 1.25; P < 0.001). In the intervention group, more prostate cancers with Gleason grade of 6 or lower were identified (1.7 versus 1.1 percent; P < 0.001).<\/p>\n
“Although longer-term follow-up is under way, the findings do not support single PSA testing for population-based screening,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n